

Peter Andreas Fasching

List of Publications by Citations

Source: <https://exaly.com/author-pdf/9520251/peter-andreas-fasching-publications-by-citations.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

435
papers

27,852
citations

75
h-index

159
g-index

465
ext. papers

35,009
ext. citations

7.9
avg, IF

5.95
L-index

#	Paper	IF	Citations
435	Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. <i>Lancet, The</i> , 2014 , 384, 164-72	40	2177
434	Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. <i>Journal of Clinical Oncology</i> , 2012 , 30, 1796-804 ²	24.2	1560
433	Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer. <i>New England Journal of Medicine</i> , 2019 , 380, 617-628	59.2	832
432	Large-scale genotyping identifies 41 new loci associated with breast cancer risk. <i>Nature Genetics</i> , 2013 , 45, 353-61, 361e1-2	36.3	813
431	Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. <i>Lancet Oncology, The</i> , 2018 , 19, 40-50	21.7	730
430	Association analysis identifies 65 new breast cancer risk loci. <i>Nature</i> , 2017 , 551, 92-94	50.4	643
429	Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case-control studies. <i>Lancet Oncology, The</i> , 2012 , 13, 385-94	21.7	612
428	Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial. <i>Lancet Oncology, The</i> , 2014 , 15, 747-56	21.7	603
427	Pembrolizumab for Early Triple-Negative Breast Cancer. <i>New England Journal of Medicine</i> , 2020 , 382, 810-821	59.2	599
426	Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies. <i>Journal of the National Cancer Institute</i> , 2011 , 103, 250-63	9.7	513
425	Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer. <i>Journal of Clinical Oncology</i> , 2015 , 33, 304-11 ²	11.2	435
424	Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3. <i>Journal of Clinical Oncology</i> , 2018 , 36, 2465-2472	2.2	435
423	Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. <i>Nature Genetics</i> , 2013 , 45, 371-84, 384e1-2	36.3	422
422	Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer. <i>New England Journal of Medicine</i> , 2012 , 366, 299-309	59.2	411
421	Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study. <i>Journal of Clinical Oncology</i> , 2010 , 28, 2024-31	2.2	410
420	Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer. <i>Nature Genetics</i> , 2015 , 47, 373-80	36.3	406
419	Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. <i>JAMA - Journal of the American Medical Association</i> , 2009 , 302, 1429-36	27.4	405

4 ¹⁸	Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups. <i>Journal of Clinical Oncology</i> , 2011 , 29, 3351-7	2.2	383
4 ¹⁷	Circulating tumor cells predict survival in early average-to-high risk breast cancer patients. <i>Journal of the National Cancer Institute</i> , 2014 , 106,	9.7	374
4 ¹⁶	Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial. <i>Lancet Oncology</i> , 2012 , 13, 135-44	21.7	363
4 ¹⁵	Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes. <i>American Journal of Human Genetics</i> , 2019 , 104, 21-34	11	363
4 ¹⁴	Genome-wide association studies identify four ER negative-specific breast cancer risk loci. <i>Nature Genetics</i> , 2013 , 45, 392-8, 398e1-2	36.3	327
4 ¹³	Prediction of breast cancer risk based on profiling with common genetic variants. <i>Journal of the National Cancer Institute</i> , 2015 , 107,	9.7	324
4 ¹²	A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24. <i>Nature Genetics</i> , 2010 , 42, 874-9	36.3	277
4 ¹¹	A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population. <i>Nature Genetics</i> , 2010 , 42, 885-92	36.3	276
4 ¹⁰	GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer. <i>Nature Genetics</i> , 2013 , 45, 362-70, 370e1-2	36.3	267
4 ⁰⁹	Genomic analyses identify hundreds of variants associated with age at menarche and support a role for puberty timing in cancer risk. <i>Nature Genetics</i> , 2017 , 49, 834-841	36.3	257
4 ⁰⁸	A common variant at the TERT-CLPTM1L locus is associated with estrogen receptor-negative breast cancer. <i>Nature Genetics</i> , 2011 , 43, 1210-4	36.3	253
4 ⁰⁷	Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer. <i>New England Journal of Medicine</i> , 2020 , 382, 514-524	59.2	251
4 ⁰⁶	A genome-wide association study identifies a new ovarian cancer susceptibility locus on 9p22.2. <i>Nature Genetics</i> , 2009 , 41, 996-1000	36.3	240
4 ⁰⁵	Genome-wide association analysis identifies three new breast cancer susceptibility loci. <i>Nature Genetics</i> , 2012 , 44, 312-8	36.3	237
4 ⁰⁴	Large-scale genomic analyses link reproductive aging to hypothalamic signaling, breast cancer susceptibility and BRCA1-mediated DNA repair. <i>Nature Genetics</i> , 2015 , 47, 1294-1303	36.3	226
4 ⁰³	Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment. <i>BMC Cancer</i> , 2011 , 11, 486	4.8	211
4 ⁰²	Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer: Secondary Analysis of the GeparSixto Randomized Clinical Trial. <i>JAMA Oncology</i> , 2017 , 3, 1378-1385	13.4	210
4 ⁰¹	Common variants at 19p13 are associated with susceptibility to ovarian cancer. <i>Nature Genetics</i> , 2010 , 42, 880-4	36.3	210

400	Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials. <i>Breast Cancer Research and Treatment</i> , 2011 , 125, 145-56	4.4	193
399	Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. <i>Nature Genetics</i> , 2017 , 49, 680-691	36.3	190
398	PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (her2) therapy in primary HER2-overexpressing breast cancer. <i>Journal of Clinical Oncology</i> , 2014 , 32, 3212-20	2.2	189
397	Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. <i>Nature Genetics</i> , 2017 , 49, 1767-1778	36.3	186
396	Identification of six new susceptibility loci for invasive epithelial ovarian cancer. <i>Nature Genetics</i> , 2015 , 47, 164-71	36.3	177
395	Capecitabine in addition to anthracycline- and taxane-based neoadjuvant treatment in patients with primary breast cancer: phase III GeparQuattro study. <i>Journal of Clinical Oncology</i> , 2010 , 28, 2015-23 ^{2,2}	17.3	173
394	Functional variants at the 11q13 risk locus for breast cancer regulate cyclin D1 expression through long-range enhancers. <i>American Journal of Human Genetics</i> , 2013 , 92, 489-503	11	167
393	Standardized evaluation of tumor-infiltrating lymphocytes in breast cancer: results of the ring studies of the international immuno-oncology biomarker working group. <i>Modern Pathology</i> , 2016 , 29, 1155-64	9.8	154
392	Dose-Response Association of CD8+ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer. <i>JAMA Oncology</i> , 2017 , 3, e173290	13.4	152
391	Triple-Negative Breast Cancer Risk Genes Identified by Multigene Hereditary Cancer Panel Testing. <i>Journal of the National Cancer Institute</i> , 2018 , 110, 855-862	9.7	145
390	A meta-analysis of genome-wide association studies of breast cancer identifies two novel susceptibility loci at 6q14 and 20q11. <i>Human Molecular Genetics</i> , 2012 , 21, 5373-84	5.6	143
389	Breast Cancer Risk Genes - Association Analysis in More than 113,000 Women. <i>New England Journal of Medicine</i> , 2021 , 384, 428-439	59.2	143
388	Low penetrance breast cancer susceptibility loci are associated with specific breast tumor subtypes: findings from the Breast Cancer Association Consortium. <i>Human Molecular Genetics</i> , 2011 , 20, 3289-303	5.6	140
387	CHEK2*1100delC heterozygosity in women with breast cancer associated with early death, breast cancer-specific death, and increased risk of a second breast cancer. <i>Journal of Clinical Oncology</i> , 2012 , 30, 4308-16	2.2	134
386	The contributions of breast density and common genetic variation to breast cancer risk. <i>Journal of the National Cancer Institute</i> , 2015 , 107,	9.7	128
385	Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer. <i>Nature Communications</i> , 2013 , 4, 1628	17.4	124
384	Genome-wide association study identifies 25 known breast cancer susceptibility loci as risk factors for triple-negative breast cancer. <i>Carcinogenesis</i> , 2014 , 35, 1012-9	4.6	121
383	Genome-wide association study identifies a common variant associated with risk of endometrial cancer. <i>Nature Genetics</i> , 2011 , 43, 451-4	36.3	121

382	Evidence of gene-environment interactions between common breast cancer susceptibility loci and established environmental risk factors. <i>PLoS Genetics</i> , 2013 , 9, e1003284	6	112
381	Age- and Tumor Subtype-Specific Breast Cancer Risk Estimates for CHEK2*1100delC Carriers. <i>Journal of Clinical Oncology</i> , 2016 , 34, 2750-60	2.2	107
380	Genome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer Types. <i>Cancer Discovery</i> , 2016 , 6, 1052-67	74.4	104
379	A transcriptome-wide association study of 229,000 women identifies new candidate susceptibility genes for breast cancer. <i>Nature Genetics</i> , 2018 , 50, 968-978	36.3	101
378	Common breast cancer susceptibility loci are associated with triple-negative breast cancer. <i>Cancer Research</i> , 2011 , 71, 6240-9	10.1	100
377	Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170. <i>Nature Genetics</i> , 2016 , 48, 374-86	36.3	93
376	Common breast cancer susceptibility variants in LSP1 and RAD51L1 are associated with mammographic density measures that predict breast cancer risk. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2012 , 21, 1156-66	4	92
375	Risk of estrogen receptor-positive and -negative breast cancer and single-nucleotide polymorphism 2q35-rs13387042. <i>Journal of the National Cancer Institute</i> , 2009 , 101, 1012-8	9.7	90
374	Evidence that breast cancer risk at the 2q35 locus is mediated through IGFBP5 regulation. <i>Nature Communications</i> , 2014 , 4, 4999	17.4	87
373	Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31. <i>Nature Communications</i> , 2013 , 4, 1627	17.4	85
372	Genome-wide association study identifies multiple loci associated with both mammographic density and breast cancer risk. <i>Nature Communications</i> , 2014 , 5, 5303	17.4	84
371	No evidence that protein truncating variants in BRIP1 are associated with breast cancer risk: implications for gene panel testing. <i>Journal of Medical Genetics</i> , 2016 , 53, 298-309	5.8	83
370	Refined histopathological predictors of BRCA1 and BRCA2 mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia. <i>Breast Cancer Research</i> , 2014 , 16, 3419	8.3	82
369	Fine-scale mapping of the FGFR2 breast cancer risk locus: putative functional variants differentially bind FOXA1 and E2F1. <i>American Journal of Human Genetics</i> , 2013 , 93, 1046-60	11	80
368	The ubiquitin-like molecule interferon-stimulated gene 15 (ISG15) is a potential prognostic marker in human breast cancer. <i>Breast Cancer Research</i> , 2008 , 10, R58	8.3	80
367	Quantification of fatty acid ethyl esters (FAEE) and ethyl glucuronide (EtG) in meconium from newborns for detection of alcohol abuse in a maternal health evaluation study. <i>Analytical and Bioanalytical Chemistry</i> , 2010 , 396, 2469-77	4.4	79
366	Neoadjuvant Trastuzumab Emtansine and Pertuzumab in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Three-Year Outcomes From the Phase III KRISTINE Study. <i>Journal of Clinical Oncology</i> , 2019 , 37, 2206-2216	2.2	78
365	Association of vitamin D levels and risk of ovarian cancer: a Mendelian randomization study. <i>International Journal of Epidemiology</i> , 2016 , 45, 1619-1630	7.8	77

364	Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses. <i>Nature Genetics</i> , 2020 , 52, 572-581	36.3	76
363	Association of ESR1 gene tagging SNPs with breast cancer risk. <i>Human Molecular Genetics</i> , 2009 , 18, 1131-9	5.9	75
362	Quality assured health care in certified breast centers and improvement of the prognosis of breast cancer patients. <i>Onkologie</i> , 2011 , 34, 362-7		75
361	The role of genetic breast cancer susceptibility variants as prognostic factors. <i>Human Molecular Genetics</i> , 2012 , 21, 3926-39	5.6	75
360	Single nucleotide polymorphisms of the aromatase gene (CYP19A1), HER2/neu status, and prognosis in breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2008 , 112, 89-98	4.4	75
359	Height and Breast Cancer Risk: Evidence From Prospective Studies and Mendelian Randomization. <i>Journal of the National Cancer Institute</i> , 2015 , 107,	9.7	74
358	Assessing interactions between the associations of common genetic susceptibility variants, reproductive history and body mass index with breast cancer risk in the breast cancer association consortium: a combined case-control study. <i>Breast Cancer Research</i> , 2010 , 12, R110	8.3	74
357	Gene panel sequencing in familial breast/ovarian cancer patients identifies multiple novel mutations also in genes others than BRCA1/2. <i>International Journal of Cancer</i> , 2017 , 140, 95-102	7.5	71
356	Neoadjuvant chemotherapy with paclitaxel and everolimus in breast cancer patients with non-responsive tumours to epirubicin/cyclophosphamide (EC) ± bevacizumab - results of the randomised GeparQuinto study (GBG 44). <i>European Journal of Cancer</i> , 2013 , 49, 2284-93	7.5	71
355	Identification of nine new susceptibility loci for endometrial cancer. <i>Nature Communications</i> , 2018 , 9, 3166	17.4	70
354	Population distribution of lifetime risk of ovarian cancer in the United States. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015 , 24, 671-676	4	67
353	Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer: A Phase 3 Randomized Clinical Trial. <i>JAMA Oncology</i> , 2021 , 7, 573-584	13.4	65
352	A Phase II Study of Talazoparib after Platinum or Cytotoxic Nonplatinum Regimens in Patients with Advanced Breast Cancer and Germline Mutations (ABRAZO). <i>Clinical Cancer Research</i> , 2019 , 25, 2717-2724	12.9	65
351	Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer. <i>Nature Communications</i> , 2016 , 7, 11375	17.4	64
350	The influence of obesity on survival in early, high-risk breast cancer: results from the randomized SUCCESS A trial. <i>Breast Cancer Research</i> , 2015 , 17, 129	8.3	63
349	Ki-67 as a prognostic molecular marker in routine clinical use in breast cancer patients. <i>Breast</i> , 2009 , 18, 135-41	3.6	63
348	Influence of mammographic density on the diagnostic accuracy of tumor size assessment and association with breast cancer tumor characteristics. <i>European Journal of Radiology</i> , 2006 , 60, 398-404	4.7	63
347	NAB-Paclitaxel Improves Disease-Free Survival in Early Breast Cancer: GBG 69-GeparSepto. <i>Journal of Clinical Oncology</i> , 2019 , 37, 2226-2234	2.2	61

346	Fine-scale mapping of the 5q11.2 breast cancer locus reveals at least three independent risk variants regulating MAP3K1. <i>American Journal of Human Genetics</i> , 2015 , 96, 5-20	11	59
345	Role of genetic polymorphisms and ovarian cancer susceptibility. <i>Molecular Oncology</i> , 2009 , 3, 171-81	7.9	59
344	Lymphedema in breast cancer survivors: assessment and information provision in a specialized breast unit. <i>Patient Education and Counseling</i> , 2007 , 66, 311-8	3.1	59
343	Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes. <i>Nature Genetics</i> , 2020 , 52, 56-73	36.3	56
342	Five endometrial cancer risk loci identified through genome-wide association analysis. <i>Nature Genetics</i> , 2016 , 48, 667-674	36.3	56
341	BRCA1/2 Mutations and Bevacizumab in the Neoadjuvant Treatment of Breast Cancer: Response and Prognosis Results in Patients With Triple-Negative Breast Cancer From the GeparQuinto Study. <i>Journal of Clinical Oncology</i> , 2018 , 36, 2281-2287	2.2	56
340	AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2019. <i>Breast Care</i> , 2019 , 14, 224-245	2.4	53
339	Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus. <i>Nature Communications</i> , 2016 , 7, 12675	17.4	53
338	Five polymorphisms and breast cancer risk: results from the Breast Cancer Association Consortium. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2009 , 18, 1610-6	4	53
337	A Phase II Randomized Study of Neoadjuvant Letrozole Plus Alpelisib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer (NEO-ORB). <i>Clinical Cancer Research</i> , 2019 , 25, 2975-2987	12.9	51
336	Characterizing mammographic images by using generic texture features. <i>Breast Cancer Research</i> , 2012 , 14, R59	8.3	51
335	The 5-HTTLPR polymorphism modulates the influence on environmental stressors on peripartum depression symptoms. <i>Journal of Affective Disorders</i> , 2012 , 136, 1192-7	6.6	49
334	Common alleles in candidate susceptibility genes associated with risk and development of epithelial ovarian cancer. <i>International Journal of Cancer</i> , 2011 , 128, 2063-74	7.5	49
333	Comparison of 6q25 breast cancer hits from Asian and European Genome Wide Association Studies in the Breast Cancer Association Consortium (BCAC). <i>PLoS ONE</i> , 2012 , 7, e42380	3.7	49
332	Intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for neoadjuvant treatment of high-risk early breast cancer (GeparOcto-GBG 84): A randomised phase III trial. <i>European Journal of Cancer</i> , 2019 , 106, 181-192	7.5	49
331	Shared genetics underlying epidemiological association between endometriosis and ovarian cancer. <i>Human Molecular Genetics</i> , 2015 , 24, 5955-64	5.6	48
330	Common non-synonymous SNPs associated with breast cancer susceptibility: findings from the Breast Cancer Association Consortium. <i>Human Molecular Genetics</i> , 2014 , 23, 6096-111	5.6	48
329	Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer. <i>Nature Communications</i> , 2019 , 10, 1741	17.4	47

328	Mammographic density as a risk factor for breast cancer in a German case-control study. <i>European Journal of Cancer Prevention</i> , 2011 , 20, 1-8	2	47
327	Fine-mapping of the HNF1B multicancer locus identifies candidate variants that mediate endometrial cancer risk. <i>Human Molecular Genetics</i> , 2015 , 24, 1478-92	5.6	46
326	Shared heritability and functional enrichment across six solid cancers. <i>Nature Communications</i> , 2019 , 10, 431	17.4	45
325	Novel Associations between Common Breast Cancer Susceptibility Variants and Risk-Predicting Mammographic Density Measures. <i>Cancer Research</i> , 2015 , 75, 2457-67	10.1	45
324	Association between a germline OCA2 polymorphism at chromosome 15q13.1 and estrogen receptor-negative breast cancer survival. <i>Journal of the National Cancer Institute</i> , 2010 , 102, 650-62	9.7	45
323	Adult body mass index and risk of ovarian cancer by subtype: a Mendelian randomization study. <i>International Journal of Epidemiology</i> , 2016 , 45, 884-95	7.8	45
322	Evidence that the 5p12 Variant rs10941679 Confers Susceptibility to Estrogen-Receptor-Positive Breast Cancer through FGF10 and MRPS30 Regulation. <i>American Journal of Human Genetics</i> , 2016 , 99, 903-911	11	43
321	Genetic Risk Score Mendelian Randomization Shows that Obesity Measured as Body Mass Index, but not Waist:Hip Ratio, Is Causal for Endometrial Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016 , 25, 1503-1510	4	42
320	Breast volumetry using a three-dimensional surface assessment technique. <i>Aesthetic Plastic Surgery</i> , 2011 , 35, 847-55	2	42
319	CYP19A1 fine-mapping and Mendelian randomization: estradiol is causal for endometrial cancer. <i>Endocrine-Related Cancer</i> , 2016 , 23, 77-91	5.7	41
318	Genetic overlap between endometriosis and endometrial cancer: evidence from cross-disease genetic correlation and GWAS meta-analyses. <i>Cancer Medicine</i> , 2018 , 7, 1978-1987	4.8	40
317	BRCA mutations and their influence on pathological complete response and prognosis in a clinical cohort of neoadjuvantly treated breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2018 , 171, 85-94	4.4	40
316	ABCB1 (MDR1) polymorphisms and ovarian cancer progression and survival: a comprehensive analysis from the Ovarian Cancer Association Consortium and The Cancer Genome Atlas. <i>Gynecologic Oncology</i> , 2013 , 131, 8-14	4.9	39
315	Association of mammographic density with hormone receptors in invasive breast cancers: results from a case-only study. <i>International Journal of Cancer</i> , 2012 , 131, 2643-9	7.5	39
314	Identification of novel genetic markers of breast cancer survival. <i>Journal of the National Cancer Institute</i> , 2015 , 107,	9.7	38
313	Association of p16 expression with prognosis varies across ovarian carcinoma histotypes: an Ovarian Tumor Tissue Analysis consortium study. <i>Journal of Pathology: Clinical Research</i> , 2018 , 4, 250-261	5.3	38
312	Genetic predisposition to in situ and invasive lobular carcinoma of the breast. <i>PLoS Genetics</i> , 2014 , 10, e1004285	6	38
311	Treatment landscape of advanced breast cancer patients with hormone receptor positive HER2 negative tumors - Data from the German PRAEGNANT breast cancer registry. <i>Breast</i> , 2018 , 37, 42-51	3.6	37

310	MicroRNA related polymorphisms and breast cancer risk. <i>PLoS ONE</i> , 2014 , 9, e109973	3.7	37
309	Fine-mapping identifies two additional breast cancer susceptibility loci at 9q31.2. <i>Human Molecular Genetics</i> , 2015 , 24, 2966-84	5.6	36
308	Interdisciplinary Screening, Diagnosis, Therapy and Follow-up of Breast Cancer. Guideline of the DGGG and the DKG (S3-Level, AWMF Registry Number 032/045OL, December 2017) - Part 1 with Recommendations for the Screening, Diagnosis and Therapy of Breast Cancer. <i>Geburtshilfe Und Frauenheilkunde</i> , 2018 , 78, 927-948	2	36
307	Identification and characterization of novel associations in the CASP8/ALS2CR12 region on chromosome 2 with breast cancer risk. <i>Human Molecular Genetics</i> , 2015 , 24, 285-98	5.6	35
306	Integrated Analysis of PTEN and p4EBP1 Protein Expression as Predictors for pCR in HER2-Positive Breast Cancer. <i>Clinical Cancer Research</i> , 2016 , 22, 2675-83	12.9	35
305	Use of complementary and integrative medicine among German breast cancer patients: predictors and implications for patient care within the PRAEGNANT study network. <i>Archives of Gynecology and Obstetrics</i> , 2017 , 295, 1239-1245	2.5	34
304	Akt and p53 are potential mediators of reduced mammary tumor growth by cloroquine and the mTOR inhibitor RAD001. <i>Biochemical Pharmacology</i> , 2012 , 83, 480-8	6	34
303	Pooled analysis of the prognostic relevance of progesterone receptor status in five German cohort studies. <i>Breast Cancer Research and Treatment</i> , 2014 , 148, 143-51	4.4	34
302	Prediction of pathological complete response and prognosis in patients with neoadjuvant treatment for triple-negative breast cancer. <i>BMC Cancer</i> , 2018 , 18, 1051	4.8	34
301	11q13 is a susceptibility locus for hormone receptor positive breast cancer. <i>Human Mutation</i> , 2012 , 33, 1123-32	4.7	33
300	Single nucleotide polymorphism D1853N of the ATM gene may alter the risk for breast cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2008 , 134, 873-82	4.9	33
299	A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk. <i>Cancer Research</i> , 2018 , 78, 5419-5430	10.1	32
298	Expression of neuroendocrine markers in different molecular subtypes of breast carcinoma. <i>BioMed Research International</i> , 2014 , 2014, 408459	3	32
297	Association of Pathologic Complete Response with Long-Term Survival Outcomes in Triple-Negative Breast Cancer: A Meta-Analysis. <i>Cancer Research</i> , 2020 , 80, 5427-5434	10.1	32
296	Impact of disease progression on health-related quality of life in patients with metastatic breast cancer in the PRAEGNANT breast cancer registry. <i>Breast</i> , 2018 , 37, 154-160	3.6	32
295	Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials. <i>Lancet Oncology</i> , 2021 , 22, 1151-1161	21.7	32
294	Genetic predisposition to ductal carcinoma in situ of the breast. <i>Breast Cancer Research</i> , 2016 , 18, 22	8.3	31
293	Candidate locus analysis of the TERT-CLPTM1L cancer risk region on chromosome 5p15 identifies multiple independent variants associated with endometrial cancer risk. <i>Human Genetics</i> , 2015 , 134, 231-45	6.3	30

292	AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2020. <i>Breast Care</i> , 2020 , 15, 294-309	2.4	30
291	Socioeconomic status and depression during and after pregnancy in the Franconian Maternal Health Evaluation Studies (FRAMES). <i>Archives of Gynecology and Obstetrics</i> , 2014 , 289, 755-63	2.5	30
290	Association of mammographic density with the proliferation marker Ki-67 in a cohort of patients with invasive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2012 , 135, 885-92	4.4	30
289	Genetic variants in the tryptophan hydroxylase 2 gene (TPH2) and depression during and after pregnancy. <i>Journal of Psychiatric Research</i> , 2012 , 46, 1109-17	5.2	30
288	Genome-wide association study identifies a possible susceptibility locus for endometrial cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2012 , 21, 980-7	4	30
287	Assessment of hepatocyte growth factor in ovarian cancer mortality. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2011 , 20, 1638-48	4	30
286	Early aberrant insulin-like growth factor signaling in the progression to endometrial carcinoma is augmented by tamoxifen. <i>International Journal of Cancer</i> , 2008 , 123, 2871-9	7.5	30
285	Did you drink alcohol during pregnancy? Inaccuracy and discontinuity of women's self-reports: On the way to establish meconium ethyl glucuronide (EtG) as a biomarker for alcohol consumption during pregnancy. <i>Alcohol</i> , 2016 , 54, 39-44	2.7	29
284	HER2 and TOP2A amplification in a hospital-based cohort of breast cancer patients: associations with patient and tumor characteristics. <i>Breast Cancer Research and Treatment</i> , 2014 , 145, 193-203	4.4	29
283	Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer.. <i>New England Journal of Medicine</i> , 2022 , 386, 556-567	59.2	29
282	Genome-wide association study of germline variants and breast cancer-specific mortality. <i>British Journal of Cancer</i> , 2019 , 120, 647-657	8.7	28
281	Genetic Data from Nearly 63,000 Women of European Descent Predicts DNA Methylation Biomarkers and Epithelial Ovarian Cancer Risk. <i>Cancer Research</i> , 2019 , 79, 505-517	10.1	28
280	Risk, Prediction and Prevention of Hereditary Breast Cancer - Large-Scale Genomic Studies in Times of Big and Smart Data. <i>Geburtshilfe Und Frauenheilkunde</i> , 2018 , 78, 481-492	2	27
279	Confirmation of 5p12 as a susceptibility locus for progesterone-receptor-positive, lower grade breast cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2011 , 20, 2222-31	4	27
278	Polymorphisms in a Putative Enhancer at the 10q21.2 Breast Cancer Risk Locus Regulate NRBF2 Expression. <i>American Journal of Human Genetics</i> , 2015 , 97, 22-34	11	26
277	Investigation of gene-environment interactions between 47 newly identified breast cancer susceptibility loci and environmental risk factors. <i>International Journal of Cancer</i> , 2015 , 136, E685-96	7.5	26
276	Genetic variants in VEGF pathway genes in neoadjuvant breast cancer patients receiving bevacizumab: Results from the randomized phase III GeparQuinto study. <i>International Journal of Cancer</i> , 2015 , 137, 2981-8	7.5	26
275	Fine-scale mapping of 8q24 locus identifies multiple independent risk variants for breast cancer. <i>International Journal of Cancer</i> , 2016 , 139, 1303-1317	7.5	26

274	Patient survival and tumor characteristics associated with CHEK2:p.I157T - findings from the Breast Cancer Association Consortium. <i>Breast Cancer Research</i> , 2016 , 18, 98	8.3	26
273	Assessment of breast cancer tumour size using six different methods. <i>European Radiology</i> , 2011 , 21, 1180-7	8	25
272	Invasive Breast Cancer: Recognition of Molecular Subtypes. <i>Breast Care</i> , 2011 , 6, 258-264	2.4	25
271	Reliability of an e-PRO Tool of EORTC QLQ-C30 for Measurement of Health-Related Quality of Life in Patients With Breast Cancer: Prospective Randomized Trial. <i>Journal of Medical Internet Research</i> , 2017 , 19, e322	7.6	25
270	Network-Based Integration of GWAS and Gene Expression Identifies a HOX-Centric Network Associated with Serous Ovarian Cancer Risk. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015 , 24, 1574-84	4	24
269	Genome-wide Analysis Identifies Novel Loci Associated with Ovarian Cancer Outcomes: Findings from the Ovarian Cancer Association Consortium. <i>Clinical Cancer Research</i> , 2015 , 21, 5264-76	12.9	24
268	Identification of new genetic susceptibility loci for breast cancer through consideration of gene-environment interactions. <i>Genetic Epidemiology</i> , 2014 , 38, 84-93	2.6	24
267	Common germline polymorphisms associated with breast cancer-specific survival. <i>Breast Cancer Research</i> , 2015 , 17, 58	8.3	24
266	Hormone replacement therapy and prognosis in ovarian cancer patients. <i>European Journal of Cancer Prevention</i> , 2013 , 22, 52-8	2	24
265	Outcome after neoadjuvant chemotherapy in estrogen receptor-positive and progesterone receptor-negative breast cancer patients: a pooled analysis of individual patient data from ten prospectively randomized controlled neoadjuvant trials. <i>Breast Cancer Research and Treatment</i> , 2013 , 137, 59-71	4.4	23
264	Shared decision-making in metastatic breast cancer: discrepancy between the expected prolongation of life and treatment efficacy between patients and physicians, and influencing factors. <i>Breast Cancer Research and Treatment</i> , 2013 , 139, 429-40	4.4	23
263	Initial Treatment of Patients with Primary Breast Cancer: Evidence, Controversies, Consensus: Spectrum of Opinion of German Specialists at the 15th International St.Gallen Breast Cancer Conference (Vienna 2017). <i>Geburtshilfe Und Frauenheilkunde</i> , 2017 , 77, 633-644	2	23
262	NATALEE: Phase III study of ribociclib (RIBO) + endocrine therapy (ET) as adjuvant treatment in hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) early breast cancer (EBC).. <i>Journal of Clinical Oncology</i> , 2019 , 37, TPS597-TPS597	2.2	23
261	Update Breast Cancer 2019 Part 3 - Current Developments in Early Breast Cancer: Review and Critical Assessment by an International Expert Panel. <i>Geburtshilfe Und Frauenheilkunde</i> , 2019 , 79, 470-482	2	22
260	Overexpression of SERBP1 (Plasminogen activator inhibitor 1 RNA binding protein) in human breast cancer is correlated with favourable prognosis. <i>BMC Cancer</i> , 2012 , 12, 597	4.8	22
259	Delivery mode and the course of pre- and postpartum depression. <i>Archives of Gynecology and Obstetrics</i> , 2012 , 286, 1407-12	2.5	22
258	Polymorphisms in inflammation pathway genes and endometrial cancer risk. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2013 , 22, 216-23	4	22
257	Two naturally occurring variants of the serotonin receptor gene HTR3C are associated with nausea in pregnancy. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2010 , 89, 7-14	3.8	22

256	Pain perception and detailed visual pain mapping in breast cancer survivors. <i>Breast Cancer Research and Treatment</i> , 2010 , 119, 105-10	4.4	22
255	Common Genetic Variation in Circadian Rhythm Genes and Risk of Epithelial Ovarian Cancer (EOC). <i>Journal of Genetics and Genome Research</i> , 2015 , 2,		22
254	Therapy Landscape in Patients with Metastatic HER2-Positive Breast Cancer: Data from the PRAEGNANT Real-World Breast Cancer Registry. <i>Cancers</i> , 2018 , 11,	6.6	22
253	Efficacy of neoadjuvant pertuzumab in addition to chemotherapy and trastuzumab in routine clinical treatment of patients with primary breast cancer: a multicentric analysis. <i>Breast Cancer Research and Treatment</i> , 2019 , 173, 319-328	4.4	22
252	Mutational Diversity and Therapy Response in Breast Cancer: A Sequencing Analysis in the Neoadjuvant GeparSepto Trial. <i>Clinical Cancer Research</i> , 2019 , 25, 3986-3995	12.9	21
251	Development and Validation of the Gene Expression Predictor of High-grade Serous Ovarian Carcinoma Molecular SubTYPE (PrOTYPE). <i>Clinical Cancer Research</i> , 2020 , 26, 5411-5423	12.9	21
250	Association of Germline Variant Status With Therapy Response in High-risk Early-Stage Breast Cancer: A Secondary Analysis of the GeparOcto Randomized Clinical Trial. <i>JAMA Oncology</i> , 2020 , 6, 744-748 ¹³⁴	13.4	21
249	Filtration based assessment of CTCs and CellSearch [®] based assessment are both powerful predictors of prognosis for metastatic breast cancer patients. <i>BMC Cancer</i> , 2018 , 18, 204	4.8	21
248	Genome-wide association study of subtype-specific epithelial ovarian cancer risk alleles using pooled DNA. <i>Human Genetics</i> , 2014 , 133, 481-97	6.3	21
247	Meconium indicators of maternal alcohol abuse during pregnancy and association with patient characteristics. <i>BioMed Research International</i> , 2014 , 2014, 702848	3	21
246	Electronic-Based Patient-Reported Outcomes: Willingness, Needs, and Barriers in Adjuvant and Metastatic Breast Cancer Patients. <i>JMIR Cancer</i> , 2017 , 3, e11	3.2	21
245	Genetic risk factors for ovarian cancer and their role for endometriosis risk. <i>Gynecologic Oncology</i> , 2017 , 145, 142-147	4.9	20
244	Prognostic effect of Ki-67 in common clinical subgroups of patients with HER2-negative, hormone receptor-positive early breast cancer. <i>Breast Cancer Research and Treatment</i> , 2019 , 175, 617-625	4.4	20
243	Common variants at the CHEK2 gene locus and risk of epithelial ovarian cancer. <i>Carcinogenesis</i> , 2015 , 36, 1341-53	4.6	20
242	International Consensus Conference for Advanced Breast Cancer, Lisbon 2019: ABC5 Consensus - Assessment by a German Group of Experts. <i>Breast Care</i> , 2020 , 15, 82-95	2.4	20
241	A network analysis to identify mediators of germline-driven differences in breast cancer prognosis. <i>Nature Communications</i> , 2020 , 11, 312	17.4	20
240	Computerized patient identification for the EMBRACA clinical trial using real-time data from the PRAEGNANT network for metastatic breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2016 , 158, 59-65	4.4	20
239	Efficacy and safety of everolimus plus exemestane in postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer: Results of the single-arm, phase IIIB 4EVER trial. <i>International Journal of Cancer</i> , 2019 , 144, 877-885	7.5	20

238	CYP2B6*6 is associated with increased breast cancer risk. <i>International Journal of Cancer</i> , 2014 , 134, 426-39	20
237	Comprehensive genetic assessment of the ESR1 locus identifies a risk region for endometrial cancer. <i>Endocrine-Related Cancer</i> , 2015 , 22, 851-61	5.7 19
236	TILGen: A Program to Investigate Immune Targets in Breast Cancer Patients - First Results on the Influence of Tumor-Infiltrating Lymphocytes. <i>Breast Care</i> , 2018 , 13, 8-14	2.4 19
235	SNP-SNP interaction analysis of NF- κ B signaling pathway on breast cancer survival. <i>Oncotarget</i> , 2015 , 6, 37979-94	3.3 19
234	Germline polymorphisms in an enhancer of PSIP1 are associated with progression-free survival in epithelial ovarian cancer. <i>Oncotarget</i> , 2016 , 7, 6353-68	3.3 19
233	ADSCs and adipocytes are the main producers in the autotaxin-lysophosphatidic acid axis of breast cancer and healthy mammary tissue in vitro. <i>BMC Cancer</i> , 2018 , 18, 1273	4.8 19
232	AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2021. <i>Breast Care</i> , 2021 , 16, 214-227	2.4 19
231	Knowledge and attitudes regarding medical research studies among patients with breast cancer and gynecological diseases. <i>BMC Cancer</i> , 2015 , 15, 587	4.8 18
230	Update Breast Cancer 2018 (Part 2) - Advanced Breast Cancer, Quality of Life and Prevention. <i>Geburtshilfe Und Frauenheilkunde</i> , 2018 , 78, 246-259	2 18
229	Prognostic relevance of Ki-67 in the primary tumor for survival after a diagnosis of distant metastasis. <i>Breast Cancer Research and Treatment</i> , 2013 , 138, 899-908	4.4 18
228	Interest in Integrative Medicine Among Postmenopausal Hormone Receptor-Positive Breast Cancer Patients in the EvAluate-TM Study. <i>Integrative Cancer Therapies</i> , 2017 , 16, 165-175	3 18
227	Endometriosis as a risk factor for ovarian or endometrial cancer - results of a hospital-based case-control study. <i>BMC Cancer</i> , 2015 , 15, 751	4.8 18
226	Epithelial-Mesenchymal Transition (EMT) Gene Variants and Epithelial Ovarian Cancer (EOC) Risk. <i>Genetic Epidemiology</i> , 2015 , 39, 689-97	2.6 18
225	Assessing the genetic architecture of epithelial ovarian cancer histological subtypes. <i>Human Genetics</i> , 2016 , 135, 741-56	6.3 18
224	Diagnosis and Therapy of Triple-Negative Breast Cancer (TNBC) - Recommendations for Daily Routine Practice. <i>Geburtshilfe Und Frauenheilkunde</i> , 2019 , 79, 605-617	2 17
223	Fine-scale mapping of the 4q24 locus identifies two independent loci associated with breast cancer risk. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015 , 24, 1680-91	4 17
222	FemZone trial: a randomized phase II trial comparing neoadjuvant letrozole and zoledronic acid with letrozole in primary breast cancer patients. <i>BMC Cancer</i> , 2014 , 14, 66	4.8 17
221	Genetic variants in the genes of the stress hormone signalling pathway and depressive symptoms during and after pregnancy. <i>BioMed Research International</i> , 2014 , 2014, 469278	3 17

220	Implementation and Feasibility of Electronic Patient-Reported Outcome (ePRO) Data Entry in the PRAEGNANT Real-Time Advanced and Metastatic Breast Cancer Registry. <i>Geburtshilfe Und Frauenheilkunde</i> , 2017 , 77, 870-878	2	16
219	Update Breast Cancer 2017 - Implementation of Novel Therapies. <i>Geburtshilfe Und Frauenheilkunde</i> , 2017 , 77, 1281-1290	2	16
218	An Electronic Patient-Reported Outcome Tool for the FACT-B (Functional Assessment of Cancer Therapy-Breast) Questionnaire for Measuring the Health-Related Quality of Life in Patients With Breast Cancer: Reliability Study. <i>Journal of Medical Internet Research</i> , 2019 , 21, e10004	7.6	16
217	No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. <i>Gynecologic Oncology</i> , 2016 , 141, 386-401	4.9	15
216	Update Breast Cancer 2019 Part 1 - Implementation of Study Results of Novel Study Designs in Clinical Practice in Patients with Early Breast Cancer. <i>Geburtshilfe Und Frauenheilkunde</i> , 2019 , 79, 256-267		15
215	Update Breast Cancer 2019 Part 2 - Implementation of Novel Diagnostics and Therapeutics in Advanced Breast Cancer Patients in Clinical Practice. <i>Geburtshilfe Und Frauenheilkunde</i> , 2019 , 79, 268-280		15
214	Update Breast Cancer 2018 (Part 1) - Primary Breast Cancer and Biomarkers. <i>Geburtshilfe Und Frauenheilkunde</i> , 2018 , 78, 237-245	2	15
213	Pathway-Based Analysis of Genome-Wide Association Data Identified SNPs in as Biomarker for Chemotherapy- Induced Neutropenia in Breast Cancer Patients. <i>Frontiers in Pharmacology</i> , 2018 , 9, 158	5.6	15
212	Update Breast Cancer 2019 Part 4 - Diagnostic and Therapeutic Challenges of New, Personalised Therapies for Patients with Early Breast Cancer. <i>Geburtshilfe Und Frauenheilkunde</i> , 2019 , 79, 1079-1089	2	15
211	Common Genetic Variation In Cellular Transport Genes and Epithelial Ovarian Cancer (EOC) Risk. <i>PLoS ONE</i> , 2015 , 10, e0128106	3.7	15
210	Assessment of mammographic density before and after first full-term pregnancy. <i>European Journal of Cancer Prevention</i> , 2010 , 19, 405-12	2	15
209	Update Breast Cancer 2020 Part 1 - Early Breast Cancer: Consolidation of Knowledge About Known Therapies. <i>Geburtshilfe Und Frauenheilkunde</i> , 2020 , 80, 277-287	2	14
208	MyD88 and TLR4 Expression in Epithelial Ovarian Cancer. <i>Mayo Clinic Proceedings</i> , 2018 , 93, 307-320	6.4	14
207	Mammographic density is the main correlate of tumors detected on ultrasound but not on mammography. <i>International Journal of Cancer</i> , 2016 , 139, 1967-74	7.5	14
206	Update Breast Cancer 2019 Part 5 - Diagnostic and Therapeutic Challenges of New, Personalised Therapies in Patients with Advanced Breast Cancer. <i>Geburtshilfe Und Frauenheilkunde</i> , 2019 , 79, 1090-1099		14
205	The SNP rs6500843 in 16p13.3 is associated with survival specifically among chemotherapy-treated breast cancer patients. <i>Oncotarget</i> , 2015 , 6, 7390-407	3.3	14
204	Predicting attention deficit hyperactivity disorder using pregnancy and birth characteristics. <i>Archives of Gynecology and Obstetrics</i> , 2018 , 298, 889-895	2.5	14
203	Correlation of mammographic density and serum calcium levels in patients with primary breast cancer. <i>Cancer Medicine</i> , 2017 , 6, 1473-1481	4.8	13

202	Translational highlights in breast cancer research and treatment: recent developments with clinical impact. <i>Current Opinion in Obstetrics and Gynecology</i> , 2019 , 31, 67-75	2.4	13
201	Characterization of Molecular Subtypes of Paget Disease of the Breast Using Immunohistochemistry and In Situ Hybridization. <i>Archives of Pathology and Laboratory Medicine</i> , 2019 , 143, 206-211	5	13
200	Gene-environment interactions involving functional variants: Results from the Breast Cancer Association Consortium. <i>International Journal of Cancer</i> , 2017 , 141, 1830-1840	7.5	13
199	Germline variation in ADAMTSL1 is associated with prognosis following breast cancer treatment in young women. <i>Nature Communications</i> , 2017 , 8, 1632	17.4	13
198	A comprehensive evaluation of interaction between genetic variants and use of menopausal hormone therapy on mammographic density. <i>Breast Cancer Research</i> , 2015 , 17, 110	8.3	13
197	2q36.3 is associated with prognosis for oestrogen receptor-negative breast cancer patients treated with chemotherapy. <i>Nature Communications</i> , 2014 , 5, 4051	17.4	13
196	Polymorphisms in estrogen metabolism and estrogen pathway genes and the risk of miscarriage. <i>Archives of Gynecology and Obstetrics</i> , 2009 , 280, 395-400	2.5	13
195	Evaluation of Pathologic Complete Response as a Surrogate for Long-Term Survival Outcomes in Triple-Negative Breast Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020 , 18, 1096-1104	7.3	13
194	A Randomized, Open-label, Presurgical, Window-of-Opportunity Study Comparing the Pharmacodynamic Effects of the Novel Oral SERD AZD9496 with Fulvestrant in Patients with Newly Diagnosed ER HER2 Primary Breast Cancer. <i>Clinical Cancer Research</i> , 2020 , 26, 4242-4249	12.9	13
193	Mendelian randomization analyses suggest a role for cholesterol in the development of endometrial cancer. <i>International Journal of Cancer</i> , 2021 , 148, 307-319	7.5	13
192	Salivary and hair cortisol as biomarkers of emotional and behavioral symptoms in 6-9 year old children. <i>Physiology and Behavior</i> , 2019 , 209, 112584	3.5	12
191	Evaluating the ovarian cancer gonadotropin hypothesis: a candidate gene study. <i>Gynecologic Oncology</i> , 2015 , 136, 542-8	4.9	12
190	Effects of prenatal alcohol consumption on cognitive development and ADHD-related behaviour in primary-school age: a multilevel study based on meconium ethyl glucuronide. <i>Journal of Child Psychology and Psychiatry and Allied Disciplines</i> , 2018 , 59, 110-118	7.9	12
189	Genetic variation at CYP3A is associated with age at menarche and breast cancer risk: a case-control study. <i>Breast Cancer Research</i> , 2014 , 16, R51	8.3	12
188	Polymorphisms in the RANK/RANKL genes and their effect on bone specific prognosis in breast cancer patients. <i>BioMed Research International</i> , 2014 , 2014, 842452	3	12
187	Clinical Relevance of Serum HER2 and Circulating Tumor Cell Detection in Metastatic Breast Cancer Patients. <i>Anticancer Research</i> , 2017 , 37, 3117-3128	2.3	12
186	Breast Cancer Polygenic Risk Score and Contralateral Breast Cancer Risk. <i>American Journal of Human Genetics</i> , 2020 , 107, 837-848	11	12
185	Therapy response and prognosis of patients with early breast cancer with low positivity for hormone receptors - An analysis of 2765 patients from neoadjuvant clinical trials. <i>European Journal of Cancer</i> , 2021 , 148, 159-170	7.5	12

184	Human leucocyte antigen class I in hormone receptor-positive, HER2-negative breast cancer: association with response and survival after neoadjuvant chemotherapy. <i>Breast Cancer Research</i> , 2019 , 21, 142	8.3	12
183	Development of central nervous system metastases as a first site of metastatic disease in breast cancer patients treated in the neoadjuvant trials GeparQuinto and GeparSixto. <i>Breast Cancer Research</i> , 2019 , 21, 60	8.3	11
182	Locoregional recurrence risk after neoadjuvant chemotherapy: A pooled analysis of nine prospective neoadjuvant breast cancer trials. <i>European Journal of Cancer</i> , 2020 , 130, 92-101	7.5	11
181	Prognostic Impact of Weight Change During Adjuvant Chemotherapy in Patients With High-Risk Early Breast Cancer: Results From the ADEBAR Study. <i>Clinical Breast Cancer</i> , 2018 , 18, 175-183	3	11
180	Prenatal Alcohol Exposure Is Associated With Adverse Cognitive Effects and Distinct Whole-Genome DNA Methylation Patterns in Primary School Children. <i>Frontiers in Behavioral Neuroscience</i> , 2018 , 12, 125	3.5	11
179	Genetic variation in mitotic regulatory pathway genes is associated with breast tumor grade. <i>Human Molecular Genetics</i> , 2014 , 23, 6034-46	5.6	11
178	Children of Prenatally Depressed Mothers: Externalizing and Internalizing Symptoms are Accompanied by Reductions in Specific Social-Emotional Competencies. <i>Journal of Child and Family Studies</i> , 2017 , 26, 3135-3144	2.3	11
177	Predicting Triple-Negative Breast Cancer Subtype Using Multiple Single Nucleotide Polymorphisms for Breast Cancer Risk and Several Variable Selection Methods. <i>Geburtshilfe Und Frauenheilkunde</i> , 2017 , 77, 667-678	2	11
176	Association of molecular subtypes with breast cancer risk factors: a case-only analysis. <i>European Journal of Cancer Prevention</i> , 2015 , 24, 484-90	2	11
175	Variation in NF- κ B signaling pathways and survival in invasive epithelial ovarian cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014 , 23, 1421-7	4	11
174	Inhibition of hyperalgesia by conditioning electrical stimulation in a human pain model. <i>Pain</i> , 2011 , 152, 1298-1303	8	11
173	Correlates of the desire for improved cosmetic results after breast-conserving therapy and mastectomy in breast cancer patients. <i>Breast</i> , 2008 , 17, 640-5	3.6	11
172	Inherited variants affecting RNA editing may contribute to ovarian cancer susceptibility: results from a large-scale collaboration. <i>Oncotarget</i> , 2016 , 7, 72381-72394	3.3	11
171	Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer - Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany. <i>Breast</i> , 2020 , 54, 88-95	3.6	11
170	Mutations in and Other Panel Genes in Patients With Metastatic Breast Cancer -Association With Patient and Disease Characteristics and Effect on Prognosis. <i>Journal of Clinical Oncology</i> , 2021 , 39, 1619-1630	2.2	11
169	Fine-Mapping of the 1p11.2 Breast Cancer Susceptibility Locus. <i>PLoS ONE</i> , 2016 , 11, e0160316	3.7	11
168	Prediction and clinical utility of a contralateral breast cancer risk model. <i>Breast Cancer Research</i> , 2019 , 21, 144	8.3	11
167	Update Breast Cancer 2020 Part 2 - Advanced Breast Cancer: New Treatments and Implementation of Therapies with Companion Diagnostics. <i>Geburtshilfe Und Frauenheilkunde</i> , 2020 , 80, 391-398	2	11

166	Digit ratio (2D:4D) and behavioral symptoms in primary-school aged boys. <i>Early Human Development</i> , 2018 , 119, 1-7	2.2	10
165	Adult height is associated with increased risk of ovarian cancer: a Mendelian randomisation study. <i>British Journal of Cancer</i> , 2018 , 118, 1123-1129	8.7	10
164	Prognostic molecular markers and neoadjuvant therapy response in anthracycline-treated breast cancer patients. <i>Archives of Gynecology and Obstetrics</i> , 2013 , 287, 337-44	2.5	10
163	Immune-related Gene Expression Predicts Response to Neoadjuvant Chemotherapy but not Additional Benefit from PD-L1 Inhibition in Women with Early Triple-negative Breast Cancer. <i>Clinical Cancer Research</i> , 2021 , 27, 2584-2591	12.9	10
162	Evaluation of soluble carbonic anhydrase IX as predictive marker for efficacy of bevacizumab: A biomarker analysis from the geparquinto phase III neoadjuvant breast cancer trial. <i>International Journal of Cancer</i> , 2019 , 145, 857-868	7.5	9
161	Transcriptome-wide association study of breast cancer risk by estrogen-receptor status. <i>Genetic Epidemiology</i> , 2020 , 44, 442-468	2.6	9
160	Comprehensive visualization of paresthesia in breast cancer survivors. <i>Archives of Gynecology and Obstetrics</i> , 2014 , 290, 135-41	2.5	9
159	Updates on the role of receptor activator of nuclear factor B/receptor activator of nuclear factor B ligand/osteoprotegerin pathway in breast cancer risk and treatment. <i>Current Opinion in Obstetrics and Gynecology</i> , 2017 , 29, 4-11	2.4	9
158	Prevalence of Circulating Tumor Cells After Adjuvant Chemotherapy With or Without Anthracyclines in Patients With HER2-negative, Hormone Receptor-positive Early Breast Cancer. <i>Clinical Breast Cancer</i> , 2017 , 17, 279-285	3	8
157	Semi-automated delineation of breast cancer tumors and subsequent materialization using three-dimensional printing (rapid prototyping). <i>Journal of Surgical Oncology</i> , 2017 , 115, 238-242	2.8	8
156	Association between mammographic density and pregnancies relative to age and BMI: a breast cancer case-only analysis. <i>Breast Cancer Research and Treatment</i> , 2017 , 166, 701-708	4.4	8
155	Self-reported Improvement in Side Effects and Quality of Life With Integrative Medicine in Breast Cancer Patients. <i>Integrative Cancer Therapies</i> , 2018 , 17, 941-951	3	8
154	History of Comorbidities and Survival of Ovarian Cancer Patients, Results from the Ovarian Cancer Association Consortium. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2017 , 26, 1470-1473	4	8
153	Ribociclib plus fulvestrant for advanced breast cancer: Health-related quality-of-life analyses from the MONALEESA-3 study. <i>Breast</i> , 2020 , 54, 148-154	3.6	8
152	Update Breast Cancer 2020 Part 3 - Early Breast Cancer. <i>Geburtshilfe Und Frauenheilkunde</i> , 2020 , 80, 1105-11148		
151	Translational Highlights in Breast and Ovarian Cancer 2019 - Immunotherapy, DNA Repair, PI3K Inhibition and CDK4/6 Therapy. <i>Geburtshilfe Und Frauenheilkunde</i> , 2019 , 79, 1309-1319	2	8
150	Anastrozole has an Association between Degree of Estrogen Suppression and Outcomes in Early Breast Cancer and is a Ligand for Estrogen Receptor β . <i>Clinical Cancer Research</i> , 2020 , 26, 2986-2996	12.9	8
149	Cross-Cancer Genome-Wide Association Study of Endometrial Cancer and Epithelial Ovarian Cancer Identifies Genetic Risk Regions Associated with Risk of Both Cancers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021 , 30, 217-228	4	7

148	A Small Hypoxia Signature Predicted pCR Response to Bevacizumab in the Neoadjuvant GeparQuinto Breast Cancer Trial. <i>Clinical Cancer Research</i> , 2020 , 26, 1896-1904	12.9	7
147	Prediction of contralateral breast cancer: external validation of risk calculators in 20 international cohorts. <i>Breast Cancer Research and Treatment</i> , 2020 , 181, 423-434	4.4	7
146	Breast cancer in young women: do BRCA1 or BRCA2 mutations matter?. <i>Lancet Oncology</i> , 2018 , 19, 150-151	21.7	7
145	Breast cancer patients' satisfaction with individual therapy goals and treatment in a standardized integrative medicine consultancy service. <i>Archives of Gynecology and Obstetrics</i> , 2018 , 298, 147-156	2.5	7
144	The UGT1A6_19_GG genotype is a breast cancer risk factor. <i>Frontiers in Genetics</i> , 2013 , 4, 104	4.5	7
143	Pooled analysis of two randomized phase III trials (PlanB/SuccessC) comparing six cycles of docetaxel and cyclophosphamide to sequential anthracycline taxane chemotherapy in patients with intermediate and high risk HER2-negative early breast cancer (n=5,923).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 522-528	2.2	7
142	TP53-based interaction analysis identifies cis-eQTL variants for TP53BP2, FBXO28, and FAM53A that associate with survival and treatment outcome in breast cancer. <i>Oncotarget</i> , 2017 , 8, 18381-18398	3.3	7
141	Association between breast cancer risk factors and molecular type in postmenopausal patients with hormone receptor-positive early breast cancer. <i>Breast Cancer Research and Treatment</i> , 2019 , 174, 453-461	4.4	7
140	The effect of participation in neoadjuvant clinical trials on outcomes in patients with early breast cancer. <i>Breast Cancer Research and Treatment</i> , 2018 , 171, 747-758	4.4	7
139	AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2021. <i>Breast Care</i> , 2021 , 16, 228-235	2.4	7
138	Differential prognostic relevance of patho-anatomical factors among different tumor-biological subsets of breast cancer: Results from the adjuvant SUCCESS A study. <i>Breast</i> , 2019 , 44, 81-89	3.6	6
137	Gemcitabine as adjuvant chemotherapy in patients with high-risk early breast cancer-results from the randomized phase III SUCCESS-A trial. <i>Breast Cancer Research</i> , 2020 , 22, 111	8.3	6
136	Association of genomic variants at the human leukocyte antigen locus with cervical cancer risk, HPV status and gene expression levels. <i>International Journal of Cancer</i> , 2020 , 147, 2458-2468	7.5	6
135	Correlates of mammographic density in B-mode ultrasound and real time elastography. <i>European Journal of Cancer Prevention</i> , 2012 , 21, 343-9	2	6
134	A careful reassessment of anthracycline use in curable breast cancer. <i>Npj Breast Cancer</i> , 2021 , 7, 134	7.8	6
133	HLA-G and HLA-F protein isoform expression in breast cancer patients receiving neoadjuvant treatment. <i>Scientific Reports</i> , 2020 , 10, 15750	4.9	6
132	Update Breast Cancer 2020 Part 4 - Advanced Breast Cancer. <i>Geburtshilfe Und Frauenheilkunde</i> , 2020 , 80, 1115-1122	2	6
131	Impact of fibroblast growth factor receptor 1 (FGFR1) amplification on the prognosis of breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2020 , 184, 311-324	4.4	6

130	Refined cut-off for TP53 immunohistochemistry improves prediction of TP53 mutation status in ovarian mucinous tumors: implications for outcome analyses. <i>Modern Pathology</i> , 2021 , 34, 194-206	9.8	6
129	Prognostic effect of low-level HER2 expression in patients with clinically negative HER2 status. <i>European Journal of Cancer</i> , 2021 , 155, 1-12	7.5	6
128	Clinical and analytical validation of Ki-67 in 9069 patients from IBCSG VIII + IX, BIG1-98 and GeparTrio trial: systematic modulation of interobserver variance in a comprehensive in silico ring trial. <i>Breast Cancer Research and Treatment</i> , 2019 , 176, 557-568	4.4	5
127	Genetic predictors of chemotherapy-related amenorrhea in women with breast cancer. <i>Fertility and Sterility</i> , 2019 , 112, 731-739.e1	4.8	5
126	Assessment of breast volume changes during human pregnancy using a three-dimensional surface assessment technique in the prospective CGATE study. <i>European Journal of Cancer Prevention</i> , 2014 , 23, 151-7	2	5
125	Visual pain mapping in endometriosis. <i>Archives of Gynecology and Obstetrics</i> , 2012 , 286, 687-93	2.5	5
124	7q21-rs6964587 and breast cancer risk: an extended case-control study by the Breast Cancer Association Consortium. <i>Journal of Medical Genetics</i> , 2011 , 48, 698-702	5.8	5
123	Neurokinin 1 receptor gene polymorphism might be correlated with recurrence rates in endometriosis. <i>Gynecological Endocrinology</i> , 2009 , 25, 726-33	2.4	5
122	Analyses of germline variants associated with ovarian cancer survival identify functional candidates at the 1q22 and 19p12 outcome loci. <i>Oncotarget</i> , 2017 , 8, 64670-64684	3.3	5
121	Factors Influencing Decision-Making for or against Adjuvant and Neoadjuvant Chemotherapy in Postmenopausal Hormone Receptor-Positive Breast Cancer Patients in the EvAluate-TM Study. <i>Breast Care</i> , 2016 , 11, 315-322	2.4	5
120	The Clinical Data Intelligence Project. <i>Informatik-Spektrum</i> , 2016 , 39, 290-300	0.3	5
119	Awareness of breast cancer incidence and risk factors among healthy women in Germany: an update after 10 years. <i>European Journal of Cancer Prevention</i> , 2019 , 28, 515-521	2	5
118	Update Breast Cancer 2018 (Part 3) - Genomics, Individualized Medicine and Immune Therapies - in the Middle of a New Era: Prevention and Treatment Strategies for Early Breast Cancer. <i>Geburtshilfe Und Frauenheilkunde</i> , 2018 , 78, 1110-1118	2	5
117	Genetic analyses of gynecological disease identify genetic relationships between uterine fibroids and endometrial cancer, and a novel endometrial cancer genetic risk region at the WNT4 1p36.12 locus. <i>Human Genetics</i> , 2021 , 140, 1353-1365	6.3	5
116	Clinical effectiveness of olaparib monotherapy in germline BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: phase IIIb LUCY interim analysis. <i>European Journal of Cancer</i> , 2021 , 152, 68-77	7.5	5
115	Disseminated tumour cells from the bone marrow of early breast cancer patients: Results from an international pooled analysis. <i>European Journal of Cancer</i> , 2021 , 154, 128-137	7.5	5
114	Influence of patient and tumor characteristics on therapy persistence with letrozole in postmenopausal women with advanced breast cancer: results of the prospective observational EvAluate-TM study. <i>BMC Cancer</i> , 2019 , 19, 611	4.8	4
113	Initial clinical results with a fusion prototype for mammography and three-dimensional ultrasound with a standard mammography system and a standard ultrasound probe. <i>Acta Radiologica</i> , 2018 , 59, 1406-1413	2	4

112	The postmenopausal hormone replacement therapy-related breast cancer risk is decreased in women carrying the CYP2C19*17 variant. <i>Breast Cancer Research and Treatment</i> , 2012 , 131, 347-50	4.4	4
111	Using automated texture features to determine the probability for masking of a tumor on mammography, but not ultrasound. <i>European Journal of Medical Research</i> , 2017 , 22, 30	4.8	4
110	Pathology of Tumors Associated With Pathogenic Germline Variants in 9 Breast Cancer Susceptibility Genes.. <i>JAMA Oncology</i> , 2022 ,	13.4	4
109	Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with risk of clear cell ovarian cancer. <i>Oncotarget</i> , 2016 , 7, 69097-69110	3.3	4
108	Risk of postmenopausal hormone therapy and patient history factors for the survival rate in women with endometrial carcinoma. <i>Archives of Gynecology and Obstetrics</i> , 2020 , 301, 289-294	2.5	4
107	Gene Expression Signatures of BRCAness and Tumor Inflammation Define Subgroups of Early-Stage Hormone Receptor-Positive Breast Cancer Patients. <i>Clinical Cancer Research</i> , 2020 , 26, 6523-6534	12.9	4
106	Characteristics and Clinical Outcome of Breast Cancer Patients with Asymptomatic Brain Metastases. <i>Cancers</i> , 2020 , 12,	6.6	4
105	The association between prenatal alcohol consumption and preschool child stress system disturbance. <i>Developmental Psychobiology</i> , 2021 , 63, 687-697	3	4
104	A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers. <i>Nature Communications</i> , 2021 , 12, 1078	17.4	4
103	Addition of triple negativity of breast cancer as an indicator for germline mutations in predisposing genes increases sensitivity of clinical selection criteria. <i>BMC Cancer</i> , 2018 , 18, 926	4.8	4
102	Breast Cancer Risk Factors and Survival by Tumor Subtype: Pooled Analyses from the Breast Cancer Association Consortium. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021 , 30, 623-642	4	4
101	rs495139 in the TYMS-ENOSF1 Region and Risk of Ovarian Carcinoma of Mucinous Histology. <i>International Journal of Molecular Sciences</i> , 2018 , 19,	6.3	3
100	Discordance in Human Epidermal Growth Factor Receptor 2 (HER2) Phenotype Between Primary Tumor and Circulating Tumor Cells in Women With HER2-Negative Metastatic Breast Cancer.. <i>JCO Precision Oncology</i> , 2017 , 1, 1-12	3.6	3
99	Common variants in breast cancer risk loci predispose to distinct tumor subtypes.. <i>Breast Cancer Research</i> , 2022 , 24, 2	8.3	3
98	Endocrine Treatment for Breast Cancer Patients Revisited-History, Standard of Care, and Possibilities of Improvement. <i>Cancers</i> , 2021 , 13,	6.6	3
97	PIWI-Like 1 and PIWI-Like 2 Expression in Breast Cancer. <i>Cancers</i> , 2020 , 12,	6.6	3
96	Progression-Free Survival and Overall Survival in Patients with Advanced HER2-Positive Breast Cancer Treated with Trastuzumab Emtansine (T-DM1) after Previous Treatment with Pertuzumab. <i>Cancers</i> , 2020 , 12,	6.6	3
95	HLA-J, a Non-Pseudogene as a New Prognostic Marker for Therapy Response and Survival in Breast Cancer. <i>Geburtshilfe Und Frauenheilkunde</i> , 2020 , 80, 1123-1133	2	3

94	Update Breast Cancer 2020 Part 5 - Moving Therapies From Advanced to Early Breast Cancer Patients. <i>Geburtshilfe Und Frauenheilkunde</i> , 2021 , 81, 469-480	2	3
93	Associations between Genetically Predicted Circulating Protein Concentrations and Endometrial Cancer Risk. <i>Cancers</i> , 2021 , 13,	6.6	3
92	Update Breast Cancer 2021 Part 1 - Prevention and Early Stages. <i>Geburtshilfe Und Frauenheilkunde</i> , 2021 , 81, 526-538	2	3
91	Association of genomic variants at PAX8 and PBX2 with cervical cancer risk. <i>International Journal of Cancer</i> , 2021 , 149, 893	7.5	3
90	Update Breast Cancer 2021 Part 3 - Current Developments in the Treatment of Early Breast Cancer: Review and Assessment of Specialised Treatment Scenarios by an International Expert Panel. <i>Geburtshilfe Und Frauenheilkunde</i> , 2021 , 81, 654-665	2	3
89	Association of Prenatal Alcohol Exposure and Prenatal Maternal Depression with Offspring Low-Grade Inflammation in Early Adolescence. <i>International Journal of Environmental Research and Public Health</i> , 2021 , 18,	4.6	3
88	Mammographic density and prognosis in primary breast cancer patients. <i>Breast</i> , 2021 , 59, 51-57	3.6	3
87	Semi-automated De-identification of German Content Sensitive Reports for Big Data Analytics. <i>RoFo Fortschritte Auf Dem Gebiet Der Rontgenstrahlen Und Der Bildgebenden Verfahren</i> , 2017 , 189, 661-671	2.3	2
86	Two truncating variants in FANCC and breast cancer risk. <i>Scientific Reports</i> , 2019 , 9, 12524	4.9	2
85	Preexisting musculoskeletal burden and its development under letrozole treatment in early breast cancer patients. <i>International Journal of Cancer</i> , 2019 , 145, 2114-2121	7.5	2
84	Using Probability for Pathological Complete Response (pCR) as a Decision Support Marker for Neoadjuvant Chemotherapy in HER2 Negative Breast Cancer Patients - a Survey Among Physicians. <i>Geburtshilfe Und Frauenheilkunde</i> , 2018 , 78, 707-714	2	2
83	Update Breast Cancer 2021 Part 5 - Advanced Breast Cancer.. <i>Geburtshilfe Und Frauenheilkunde</i> , 2022 , 82, 215-225	2	2
82	Breast cancer treatment with everolimus and exemestane for ER+ women: Results of the first interim analysis of the noninterventional trial BRAWO.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 578-578	2.2	2
81	A randomized phase II trial to assess the efficacy of paclitaxel and olaparib in comparison to paclitaxel / carboplatin followed by epirubicin / cyclophosphamide as neoadjuvant chemotherapy in patients with HER2-negative early breast cancer and homologous recombination deficiency (HRD): <i>Journal of Clinical Oncology</i> , 2014 , 32, 578-578	2.2	2
80	MCM3 is a novel proliferation marker associated with longer survival for patients with tubo-ovarian high-grade serous carcinoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2021 ,	5.1	2
79	Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses		2
78	Assessment of the additional clinical potential of X-ray dark-field imaging for breast cancer in a preclinical setup. <i>Therapeutic Advances in Medical Oncology</i> , 2020 , 12, 1758835920957932	5.4	2
77	Germline BRCA1/2 mutations and severe haematological toxicities in patients with breast cancer treated with neoadjuvant chemotherapy. <i>European Journal of Cancer</i> , 2021 , 145, 44-52	7.5	2

76	Update Breast Cancer 2021 Part 2 - Advanced Stages, Long-Term Consequences and Biomarkers. <i>Geburtshilfe Und Frauenheilkunde</i> , 2021 , 81, 539-548	2	2
75	Subgroup of post-neoadjuvant luminal-B tumors assessed by HTG in PENELOPE-B investigating palbociclib in high risk HER2-/HR+ breast cancer with residual disease.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 519-519	2.2	2
74	Identification of a Locus Near Associated With Progression-Free Survival in Ovarian Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021 , 30, 1669-1680	4	2
73	The impact of mammalian target of rapamycin inhibition on bone health in postmenopausal women with hormone receptor-positive advanced breast cancer receiving everolimus plus exemestane in the phase IIIb 4EVER trial. <i>Journal of Bone Oncology</i> , 2019 , 14, 010-10	4.5	2
72	CYP3A7*1C allele: linking premenopausal oestrone and progesterone levels with risk of hormone receptor-positive breast cancers. <i>British Journal of Cancer</i> , 2021 , 124, 842-854	8.7	2
71	Update Breast Cancer 2018 (Part 4) - Genomics, Individualized Medicine and Immune Therapies - in the Middle of a New Era: Treatment Strategies for Advanced Breast Cancer. <i>Geburtshilfe Und Frauenheilkunde</i> , 2018 , 78, 1119-1128	2	2
70	Germline genome-wide association studies in women receiving neoadjuvant chemotherapy with or without bevacizumab. <i>Pharmacogenetics and Genomics</i> , 2018 , 28, 147-152	1.9	2
69	Klinische Endpunkte in Real-World-Register-Studien. <i>Onkologe</i> , 2020 , 26, 530-541	0.1	1
68	ABC5 International Consensus Conference on Advanced Breast Cancer, Lisbon, 16 November 2019: Commentary by the German panel of experts on the ABC5 voting results. <i>Geburtshilfe Und Frauenheilkunde</i> , 2020 , 80, 588-600	2	1
67	Genetic polymorphisms and correlation with treatment induced cardiotoxicity and prognosis in breast cancer patients.. <i>Clinical Cancer Research</i> , 2022 ,	12.9	1
66	Update Breast Cancer 2021 Part 4 - Prevention and Early Stages.. <i>Geburtshilfe Und Frauenheilkunde</i> , 2022 , 82, 206-214	2	1
65	Survival analysis of the randomised phase III GeparOcto trial comparing neoadjuvant chemotherapy of intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for patients with high-risk early breast cancer. <i>European Journal of Cancer</i> , 2021 ,	7.5	1
64	Common variants in breast cancer risk loci predispose to distinct tumor subtypes		1
63	Does anxiety impact the neural processing of child faces in mothers of school-aged children? An ERP study using an emotional Go/NoGo task. <i>Social Neuroscience</i> , 2020 , 15, 530-543	2	1
62	Treatment Landscape and Prognosis After Treatment with Trastuzumab Emtansine. <i>Geburtshilfe Und Frauenheilkunde</i> , 2020 , 80, 1134-1142	2	1
61	Breast MRI texture analysis for prediction of BRCA-associated genetic risk. <i>BMC Medical Imaging</i> , 2020 , 20, 86	2.9	1
60	Treatment of Patients with Early Breast Cancer: Evidence, Controversies, Consensus: German Expert Opinions on the 17th International St.Gallen Consensus Conference. <i>Geburtshilfe Und Frauenheilkunde</i> , 2021 , 81, 637-653	2	1
59	Functional annotation of the 2q35 breast cancer risk locus implicates a structural variant in influencing activity of a long-range enhancer element. <i>American Journal of Human Genetics</i> , 2021 , 108, 1190-1203	11	1

58	Prenatal Alcohol Exposure and the Facial Phenotype in Adolescents: A Study Based on Meconium Ethyl Glucuronide. <i>Brain Sciences</i> , 2021 , 11,	3.4	1
57	Challenges and Opportunities for Real-World Evidence in Metastatic Luminal Breast Cancer. <i>Breast Care</i> , 2021 , 16, 108-114	2.4	1
56	Supportive Infusions in Integrative Breast and Gynecological Oncology - Report on Patients' Satisfaction and Self-reported Effects and Side Effects. <i>Geburtshilfe Und Frauenheilkunde</i> , 2018 , 78, 1129-1137 ¹		
55	Association of germline genetic variants with breast cancer-specific survival in patient subgroups defined by clinic-pathological variables related to tumor biology and type of systemic treatment. <i>Breast Cancer Research</i> , 2021 , 23, 86	8.3	1
54	Abstract PD8-01: Phase 3 SOPHIA study of margetuximab (M) + chemotherapy (CTX) vs trastuzumab (T) + CTX in patients (pts) with HER2+ metastatic breast cancer (MBC) after prior anti-HER2 therapies: Final overall survival (OS) analysis. <i>Cancer Research</i> , 2022 , 82, PD8-01-PD8-01	10.1	1
53	The impact of anthracyclines in intermediate and high-risk HER2-negative early breast cancer-a pooled analysis of the randomised clinical trials PlanB and SUCCESS C.. <i>British Journal of Cancer</i> , 2022 ,	8.7	1
52	Abstract PD13-06: Neoadjuvant giredestrant (GDC-9545) + palbociclib versus anastrozole + palbociclib in postmenopausal women with estrogen receptor-positive, HER2-negative, untreated early breast cancer: Primary analysis of the randomized, open-label, phase II coopERA breast cancer study. <i>Cancer Research</i> , 2022 , 82, PD13-06-PD13-06	10.1	1
51	Comparison of C-Reactive Protein in Dried Blood Spots and Saliva of Healthy Adolescents.. <i>Frontiers in Immunology</i> , 2021 , 12, 795580	8.4	1
50	Update Breast Cancer 2022 Part 2 ▯Advanced Stage Breast Cancer. <i>Geburtshilfe Und Frauenheilkunde</i> , 2022 , 82, 590-600	2	1
49	Update Mammakarzinom 2019 Teil 3 ▯aktuelle Entwicklungen bei der kurativen Behandlung von Mammakarzinompatientinnen: eine Bersicht und Bewertung durch ein internationales Expertenpanel. <i>Senologie - Zeitschrift F▯ Mammadiagnostik Und -therapie</i> , 2019 , 16, 123-136	0	0
48	RANKL and OPG and their influence on breast volume changes during pregnancy in healthy women. <i>Scientific Reports</i> , 2020 , 10, 5171	4.9	0
47	Rare germline copy number variants (CNVs) and breast cancer risk.. <i>Communications Biology</i> , 2022 , 5, 65	6.7	0
46	ABC6 Consensus: Assessment by a Group of German Experts.. <i>Breast Care</i> , 2022 , 17, 90-100	2.4	0
45	Prevalence of SARS-CoV-2 in Pregnant Women Assessed by RT-PCR in Franconia, Germany: First Results of the SCENARIO Study (SARS-CoV-2 prEvalence in pregnANcy and at biRth In Franconia).. <i>Geburtshilfe Und Frauenheilkunde</i> , 2022 , 82, 226-234	2	0
44	Germline variants and breast cancer survival in patients with distant metastases at primary breast cancer diagnosis. <i>Scientific Reports</i> , 2021 , 11, 19787	4.9	0
43	Implementation of an Electronic Patient-Reported Outcome App for Health-Related Quality of Life in Breast Cancer Patients: Evaluation and Acceptability Analysis in a Two-Center Prospective Trial.. <i>Journal of Medical Internet Research</i> , 2022 , 24, e16128	7.6	0
42	Heregulin (HRG) assessment for clinical trial eligibility testing in a molecular registry (PRAEGNANT) in Germany. <i>BMC Cancer</i> , 2020 , 20, 1091	4.8	0
41	Patterns and Trends of Herbal Medicine Use among Patients with Gynecologic Cancer. <i>Geburtshilfe Und Frauenheilkunde</i> , 2021 , 81, 699-707	2	0

40	Diagnostic Accuracy of Breast Medical Tactile Examiners (MTEs): A Prospective Pilot Study. <i>Breast Care</i> , 2019 , 14, 41-47	2.4	○
39	Update Mammakarzinom 2019 Teil 1 Implementierung der Ergebnisse neuer Studienkonzepte beim frühen Mammakarzinom in die klinische Praxis. <i>Tumor Diagnostik Und Therapie</i> , 2019 , 40, 433-444	0.1	○
38	Analysis of Oncological Second Opinions in a Certified University Breast and Gynecological Cancer Center Regarding Consensus between the First and Second Opinion and Conformity with the Guidelines. <i>Breast Care</i> , 2021 , 16, 291-298	2.4	○
37	Genetic variations in estrogen and progesterone pathway genes in preeclampsia patients and controls in Bavaria. <i>Archives of Gynecology and Obstetrics</i> , 2021 , 303, 897-904	2.5	○
36	Comparison of methods for isolation and quantification of circulating cell-free DNA from patients with endometriosis. <i>Reproductive BioMedicine Online</i> , 2021 , 43, 788-798	4	○
35	Mendelian randomisation study of smoking exposure in relation to breast cancer risk. <i>British Journal of Cancer</i> , 2021 , 125, 1135-1145	8.7	○
34	Comprehensive characterization of endometriosis patients and disease patterns in a large clinical cohort. <i>Archives of Gynecology and Obstetrics</i> , 2021 , 1	2.5	○
33	Heart Rate Measurement Accuracy of Fitbit Charge 4 and Samsung Galaxy Watch Active2: Device Evaluation Study.. <i>JMIR Formative Research</i> , 2022 , 6, e33635	2.5	○
32	Update Mammakarzinom 2021 Teil 3 Aktuelle Entwicklungen bei der Behandlung von Brustkrebspatientinnen mit frühen Krankheitsstadien: Übersicht und Beurteilung von speziellen Therapiesituationen durch ein internationales Expertenpanel. <i>Senologie - Zeitschrift Für Mammadiagnostik Und -therapie</i> , 2022 , 19, 75-87	○	○
31	Unterstützende Infusionen in der integrativen Onkologie bei Brustkrebs und gynäkologischen Krebserkrankungen Bericht über die Zufriedenheit der Patientinnen sowie über selbstberichtete Wirkungen und Nebenwirkungen. <i>Senologie - Zeitschrift Für Mammadiagnostik Und -therapie</i> , 2019 , 16, 137-146	○	○
30	Update Mammakarzinom 2018 (Teil 3) Genomforschung, individualisierte Medizin und Immuntherapien Mitten in einer neuen Era: Prävention und Therapie des frühen Mammakarzinoms. <i>Senologie - Zeitschrift Für Mammadiagnostik Und -therapie</i> , 2019 , 16, 23-32	○	○
29	Update Mammakarzinom 2019 Teil 1 Implementierung der Ergebnisse neuer Studienkonzepte beim frühen Mammakarzinom in die klinische Praxis. <i>Senologie - Zeitschrift Für Mammadiagnostik Und -therapie</i> , 2019 , 16, 33-44	○	○
28	Neoadjuvant Treatment of HER2-Positive Breast Cancer A Review 2019 , 95-106		
27	Update Mammakarzinom 2017 Etablierung neuer zielgerichteter Therapien. <i>Senologie - Zeitschrift Für Mammadiagnostik Und -therapie</i> , 2018 , 15, 31-40	○	○
26	Update Mammakarzinom 2018 (Teil 1) Primäres Mammakarzinom und Biomarker. <i>Senologie - Zeitschrift Für Mammadiagnostik Und -therapie</i> , 2018 , 15, 86-94	○	○
25	Response to Di Cosimo, Torri, and Porcu. <i>Journal of the National Cancer Institute</i> , 2019 , 111, 1234-1235	9.7	
24	Response to "screening depression during and after pregnancy using the EPDS". <i>Archives of Gynecology and Obstetrics</i> , 2014 , 290, 603	2.5	
23	Standard Changing News der Senologie und Gynäkologischen Onkologie. <i>Klinikerzt</i> , 2017 , 46, 648-654	○	

22	Implementation and Feasibility of Electronic Patient-Reported Outcome (ePRO) Data Entry in the PRAEGNANT Real-Time Advanced and Metastatic Breast Cancer Registry. <i>Senologie - Zeitschrift für Mammadiagnostik Und -therapie</i> , 2017 , 14, 221-230	0
21	A phase II single-arm, multicenter, open-label neoadjuvant study of pembrolizumab in combination with nab-paclitaxel followed by pembrolizumab in combination with epirubicin and cyclophosphamide in patients with triple-negative breast cancer: Neoimmunoboost.. <i>Journal of Clinical Oncology</i> , 2020 , 38, e12647-e12647	2.2
20	Risikoadaptierte Diagnostik und Therapie 2017 , 43-53	
19	Zukünftige Entwicklungen in der Bildgebung 2017 , 201-218	
18	ABC5 Internationale Konsensuskonferenz zum fortgeschrittenen Mammakarzinom, Lissabon, 16.11.2019 Deutsche Expertengruppe kommentiert ABC5-Abstimmungsergebnisse. <i>Senologie - Zeitschrift für Mammadiagnostik Und -therapie</i> , 2020 , 17, 173-186	0
17	Translational Highlights Mamma- und Ovarialkarzinom 2019 Immuntherapien, DNA-Reparatur, PI3K-Inhibition und CDK4/6-Therapien. <i>Senologie - Zeitschrift für Mammadiagnostik Und -therapie</i> , 2020 , 17, 31-41	0
16	Behandlung von Patientinnen mit frühem Mammakarzinom: Evidenz, Kontroversen, Konsens und Meinungsbild deutscher Expert*innen zur 17. Internationalen St.-Gallen-Konsensuskonferenz. <i>Senologie - Zeitschrift für Mammadiagnostik Und -therapie</i> , 2021 , 18, 163-181	0
15	Update Mammakarzinom 2019 Teil 5 Diagnostische und therapeutische Herausforderungen neuer personalisierter Therapien bei Patientinnen mit fortgeschrittenem Mammakarzinom. <i>Senologie - Zeitschrift für Mammadiagnostik Und -therapie</i> , 2019 , 16, 292-301	0
14	Diagnostik und Therapie des triple-negativen Mammakarzinoms (TNBC) Empfehlungen für die tägliche Routine. <i>Senologie - Zeitschrift für Mammadiagnostik Und -therapie</i> , 2019 , 16, 219-231	0
13	Update Mammakarzinom 2019 Teil 3 Aktuelle Entwicklungen bei der kurativen Behandlung von Mammakarzinom-Patientinnen: Eine Übersicht und Bewertung durch ein internationales Expertenpanel. <i>Tumor Diagnostik Und Therapie</i> , 2019 , 40, 459-472	0.1
12	Update Mammakarzinom 2019 Teil 2 Implementierung neuer Diagnostika und Therapien bei Patientinnen mit fortgeschrittenem Brustkrebs in der klinischen Praxis. <i>Tumor Diagnostik Und Therapie</i> , 2019 , 40, 445-458	0.1
11	Influence of Family History of Breast or Ovarian Cancer on Pathological Complete Response and Long-Term Prognosis in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy. <i>Breast Care</i> , 2021 , 16, 254-262	2.4
10	Genetic variants in the glucocorticoid pathway genes and birth weight. <i>Archives of Gynecology and Obstetrics</i> , 2021 , 303, 427-434	2.5
9	Active Participation, Mind-Body Stabilization, and Coping Strategies with Integrative Medicine in Breast Cancer Patients. <i>Integrative Cancer Therapies</i> , 2021 , 20, 1534735421990108	3
8	NGS zur Selektion innovativer Therapien Was bringt das?. <i>Der Gynakologe</i> , 2021 , 54, 164-174	0.1
7	Update Mammakarzinom 2020 Teil 3 Frühes Mammakarzinom. <i>Senologie - Zeitschrift für Mammadiagnostik Und -therapie</i> , 2021 , 18, 39-48	0
6	Update Mammakarzinom 2020 Teil 4 Fortgeschrittenes Mammakarzinom. <i>Senologie - Zeitschrift für Mammadiagnostik Und -therapie</i> , 2021 , 18, 49-57	0
5	Update Mammakarzinom 2018 (Teil 2) Fortgeschrittenes Mammakarzinom, Lebensqualität und Prävention. <i>Senologie - Zeitschrift für Mammadiagnostik Und -therapie</i> , 2018 , 15, 95-108	0

- 4 Update Mammakarzinom 2020 Teil 5 Einführung von Substanzen aus der metastasierten
Therapiesituation in die frühe Therapiesituation. *Senologie - Zeitschrift für Mammadiagnostik Und
-therapie*, **2021**, 18, 254-265 0
- 3 Das Nicht-Pseudogen HLA-J ist ein neuer prognostischer Marker für das Ansprechen auf Therapie
und das Überleben bei Brustkrebs. *Senologie - Zeitschrift für Mammadiagnostik Und -therapie*, **2021**,
18, 353-364 0
- 2 Update Mammakarzinom 2021 Teil 1 Prävention und frühe Krankheitsstadien. *Senologie -
Zeitschrift für Mammadiagnostik Und -therapie*, **2021**, 18, 377-390 0
- 1 Update Breast Cancer 2022 Part 1 Early Stage Breast Cancer. *Geburtshilfe Und Frauenheilkunde*,
2022, 82, 580-589 2